Small-airway disease and its reversibility in human immunodeficiency virus-infected children on highly active antiretroviral therapy: A cross-sectional study in an African setting

Adaeze C. Ayuk¹,², Chizalu I. Ndukwu³, Samuel N. Uwaezuoke¹,²

Abstract:

BACKGROUND: Lung function abnormalities may occur in children with human immunodeficiency virus (HIV) infection. Small-airway disease (SAD) precedes abnormalities in forced expiratory volume in 1 s (FEV₁).

OBJECTIVE: This study aims to assess the presence and reversibility of SAD in HIV-infected children using the Global Lung Function Initiative standards.

METHODS: A cross-sectional study was conducted over 6 months at the Paediatric HIV Clinic of the University of Nigeria Teaching Hospital in Enugu, Southeast Nigeria. Eligible consenting children with HIV infection were recruited. Lung function was measured, and the reversibility of FEV₁ and forced vital capacity (FVC) was assessed at 12% while that of forced expiratory flow between 25% and 75% (FEF₂⁵‑₇⁵) was assessed at 12%, 15%, and 20%. Predictors of abnormal Z-score values were determined by multivariate linear and logistic regressions. Statistically significant values were set at \( P < 0.05 \).

RESULTS: The mean Z-score for FEV₁, FVC, and FEF₂⁵‑₇⁵ was −2.19, −1.86, and −1.60, respectively. Most patients (73%) had abnormal FEV₁, while 52% had abnormal FEF₂⁵‑₇⁵. Significant changes in FEV₁ (\( P = 0.001 \)) and FEF₂⁵‑₇⁵ (\( P < 0.001 \)) occurred after the bronchodilator response (BDR) test. Of the children whose FEV₁ showed positive BDR, 70.9% had low zFEV₁; 50% had low zFEF₂⁵‑₇⁵, while all had low FEV₁. Nutritional status (Z-score for body mass index) was significantly associated with low FEV₁.

CONCLUSIONS: Abnormal FEF₂⁵‑₇⁵ as a marker of SAD and FEV₁ with a positive BDR are common in HIV-infected children. These lung function abnormalities justify long-term follow-up for these patients.

Keywords: Africa, children, human immunodeficiency virus, Nigeria, small-airway disease, spirometry

Human immunodeficiency virus (HIV) infection in children remains a global health challenge. Fortunately, highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality among infected children. Despite prolonged patient survival and the favorable outcome from eliminating the frequent chest infections, HIV still causes airway hyper-responsiveness and obstruction over time. The pathophysiologic trajectory involves a rapid progression to asthma and...
chonic obstructive pulmonary disease later in adult life.[4,6]

Forced expiratory volume in 1 s (FEV₁) mainly reflects obstruction in the larger airways.[6] However, a significant degree of small-airway disease (SAD) precedes abnormalities in FEV₁.[6] Examination of the mid-portion of expiratory flow may, therefore, offer more information on small-airway pathology. The forced expiratory flow between 25% and 75% (FEF 25–75) of the forced vital capacity (FVC) is one of the most commonly used parameters of small-airway pathology.[6‑9] Besides its inaccuracy in assessing SAD, the lung clearance index is usually limited to research laboratories due to cost, expertise, and availability.[6] Low FEF 25–75 is a sensitive marker for airway obstruction in asymptomatic asthmatics[10] and a known marker of methacholine responsiveness in symptomatic asthmatic children.[11] It also predicts bronchodilator response (BDR) to albuterol.[9]

Spirometry has been used to evaluate HIV-related lung changes in children, and abnormalities in FEV₁, FVC, and low FEV/FVC have been reported.[12‑14] Furthermore, other authors reported positive BDR in HIV-infected children.[13‑15] It is postulated that if SAD exists in these children, surrogate parameters such as FEV₁ and the additional use of FEF 25–75 could help to identify them on time. The present study thus focuses on detecting lung function abnormalities in HIV-infected children, with emphasis on FEF 25–75 as an early marker of SAD. Using the more robust Global Lung Function Initiative (GLI) standards,[16] we aimed to assess the presence and reversibility of SAD in HIV-infected children. The possible risk factors for their lung function abnormalities were also evaluated.

Methods

Study site, participants’ selection, and procedures

Ethical approval was obtained from the Health Research and Ethics Committee (HREC) of the University of Nigeria Teaching Hospital, Ituku-Ozalla, Enugu, before commencing the study (Approval number: HREC/05/01/2008B). The study was cross sectional and was conducted over 6 months (from March to September 2019) at the Pediatric HIV Clinic of the hospital. Eligible individuals were previously diagnosed HIV-infected children, already registered and attending the Pediatric HIV Clinic, and children who gave assent or had informed written consent signed by their caregivers. Data were collected with interviewer-administered questionnaires and extraction of data from medical records. Extracted information from participants included age, gender, current and previous health status, and the HAART medications they were receiving. HAART was defined as the use of at least three medications from two classes of antiretroviral drugs within the previous 3 months as determined from information obtained from each patient’s filed records. Socioeconomic class (SEC) was determined by standard methods using parental level of education and type of vocation, and these were categorized into lower Class 3 (SEC 4 and 5), middle Class 2 (SEC 2 and 3), and upper Class 1 (SEC 1).[17] Children who had physician-diagnosed or self-reported asthma or had been on any bronchodilator medications or had a new or increasing cough, shortness of breath, or fever in the past 4 weeks or were severely ill or could not meet the American Thoracic Society (ATS) requirement for acceptable and reproducible spirometry[18] were excluded. The weight and standing height of each participant were measured, and subsequently, the height-for-age Z-score and body mass index (BMI) were calculated. The spirometry procedure was explained and demonstrated with the ATS/ European Respiratory Society (ERS) guidelines.[19] We used ATS-certified handheld ndd EasyOne™ spirometers, portable and battery operated. The spirometers were calibrated before and after each measurement sessions using a certified 3 L syringe. Each child was given the opportunity to make a maximum of 8 attempts, and 3 acceptable and repeatable maneuvers were selected. Any participant who failed to meet these criteria was further excluded from the study. This was done till the sample size was consecutively reached. Flow–volume curves were also manually inspected to ensure that acceptability criteria were met. After the successful prebronchodilator blow, each participant then received 400 µg of salbutamol from a pressurized metered-dose inhaler (pMDI) device in four separate doses of 100 µg through a spacer, and spirometry was repeated after 15 min.[18‑20] The value used for cut-off decision point in deciding abnormality in Bronchodilator response (BDR) for FEV₁ and FVC was done using 12% change from baseline while that for FEF 25–75 was done using all 3:12%, 15%, and 20% change from baseline.

The pre- and post-BDR values of FEV₁, FVC, FEV₁/FVC ratio, and FEF 25–75 for each participant were obtained and expressed as Z-scores. The participants were subsequently reviewed according to the HIV clinic protocol. Those with abnormal lung function patterns were counseled appropriately and given appointments for future follow-up in the children’s respiratory clinic.

Sample size and statistical analysis

Using the standard deviation (SD) of FVC in a cohort of HIV-infected children for sample size calculation,[12] a minimum sample size of 90 participants was required. The Shapiro–Wilk test was used to test for normality for continuous variables. The records of the absolute values were first stored within the spirometer and all identifiers anonymized. They were then exported to the GLI reference equations software where they were adjusted for standing height, age, sex, and ethnicity to obtain the corresponding Z-scores, predicted values,
and the lower limit of normal (LLN) values (defined as 1.64 SD below the mean and describes the lowest fifth centile). A positive change of up to 20% was applied to increase the specificity and sensitivity of FEF25-75-related BDR response, given several disadvantages of relying on FEF25-75.

The proportion of participants with airway obstruction as determined by both lung function values below the 5% lower limit of normal adjusted for age and FEV/FVC less than 0.80 were calculated. Thus the disease abnormality classification for the spirometry patterns obtained were: 'normal' if the FEV1 and FVC values were simultaneously ≥LLN; and categorized as 'obstructive' if the FEV/FVC was either < LLN or less than 80% of absolute percentage value; and as ‘restrictive pattern’, ‘fixed airway obstruction’ or ‘mixed’ if the FVC is <LLN or both the FEV1/FVC and FVC are <LLN. The paired t-test for the pre- and post-BDR mean scores and Chi-square tests for categorical variables were calculated. Univariate analyses were performed to determine variables associated with FEV1, FVC, and FEV1/FVC. We used multivariate linear and logistic regressions to determine the predictors of abnormal Z-score values of the spirometric lung function parameters. Significant findings were represented in tables and figures. Statistically significant values were set at P < 0.05.

## Results

### Characteristics of study participants

Of the eligible 104 participants (out of a total of 137 that performed spirometry), the mean age was 13.96 ± 3.23 years, with 56/104 (53.8%) males [Table 1]. There were no self-reported active smokers or exposure to environmental tobacco smoke. There was no reported personal or family history of asthma in the eligible group, and none of the participants was on treatment for tuberculosis or any other chronic respiratory disease. A total of 67/104 (64.4%) participants resided in rural or semi-urban settings, and the social status showed that 25/104 (24.0%) and 39/104 (37.5%), respectively, belonged to the middle SEC 3 and lower SEC 4. Seventy-seven participants (74.0%) were still on first-line HAART, while 27/104 (26.0%) received an alternative to mainstream first-line HAART, such as dolutegravir or the second-line HAART [Table 1].

### Lung function outcome in children with human immunodeficiency virus

For all participants, the prebronchodilator mean Z-score for FEV1 was −0.81 ± 1.18, and −0.52 ± 1.65 for FVC and FEF25-75, respectively [Table 2]. The significant changes after BDR were noted for the FEV1 (P = 0.001) and FEF25-75 (P < 0.001) [Table 3]. The bronchodilator percentage change of 3.98%, 0.63%, and 20.72% was, respectively, documented for FEV1, FVC, and FEF25-75 [Figure 1]. The value of FEV1/FVC (SD) when the mean value was calculated for all study participants was normal, 82.44% (7.34).

### Categorized prebronchodilator response patterns of lung function abnormalities among children with human immunodeficiency virus

When the lung function outcome was categorized using the 1.64 Z-score cutoff that corresponds to the LLN, 76 participants (73%) had abnormal FEV1. There were 44 participants (42%) with abnormal FVC, while 54 (52%) had abnormal FEF25-75. However, the FEV1/FVC was normal in 77 (74.0%) of the study population, as shown in Table 4.

### Categorized postbronchodilator response assessment of various lung functions and the abnormal forced expiratory volume in 1 s association with other lung function parameters

Postbronchodilator lung function parameters after salbutamol administration were also assessed. The FEV1 is the most affected component in the majority of the children, which further served as the baseline to detect other underlying pathologies.

### Forced expiratory volume in 1 s

Among all study participants, there were 55/104 (52.4%) of the children whose FEV1 showed positive BDR; and of these, more than half, 39/55 (70.9%) had low zFEV1.
When the cutoff was at 15% change, 35 (63.6%) were BDR positive, and even when the cutoff bar was further raised to positive BDR of ≥20%, more than half of that population (29, 52.7%) with abnormally low FEV$_1$ were still BDR positive. The remaining 30% of the cohort with low zFEV$_1$, showed irreversible airway obstruction, i.e., abnormally low zFEV$_1$, with no substantial response to salbutamol. In all the children with abnormal FEV$_1$, their mean lung function (pre- and post-BDR) showed that the zFEV$_1$ and zFEF$_{25-75}$ were the most affected [Table 5].

**Forced expiratory volume/forced vital capacity**

When assessed specifically, the values of FEV/FVC that measured 80% and above (mean of 82.44%) were found in 74% of the proportion of all study participants. Of these assessed children, 66.2% had abnormally low FEV$_1$. Furthermore, 90.9% showed no significant change in FEV$_1$ with BDR using the 12% cutoff.

**Forced vital capacity**

Among all our participants, 57.7% had low zFVC. Among these, those who had both low zFEV$_1$ and nonsignificant BDR response were 59/60 (98.3%) and 52/60 (86.7%), respectively, suggesting a restrictive lung pathology.

**Forced expiratory flow between 25% and 75%**

Assessing the small airways using the value of zFEF$_{25-75}$ showed that about half of the study population had low zFEF$_{25-75}$ and all of them in this category had low FEV$_1$. The reversibility in that subset was also minimal as 42/50 (82%) had reversibility of less than 12%.

### Risk factors for low forced expiratory volume in 1s in children with human immunodeficiency virus

Except for nutritional status (Z-score for BMI [zBMI]), no other characteristics (age, gender, and social status) were significantly associated with low FEV$_1$ [Table 6].

#### Discussion

Despite abnormal lung function parameters suggestive of SAD in HIV-infected children, conventional parameters for assessing the pathology are inaccurate, costly, and rarely accessible. An accessible method of measuring these abnormal parameters, such as spirometry, will facilitate the early identification of SAD in these children.

In this study, we measured surrogate parameters of SAD such as FEV$_1$ and FEF$_{25-75}$ which could identify the disease early in HIV-infected children. The reversibility of SAD was assessed by positive BDR in these lung function parameters. We demonstrated that different lung function abnormalities occur in these children, ranging from obstructive pathologies to restrictive, mixed, or fixed airway disease. When compared with the findings from a South African study, our outcome lung function mean values were different. The authors reported much
Table 4: Pattern of prebronchodilator abnormalities in lung function

| Categorized lung function variables (normal Z≥−1.64) | FEV (%) | Pre-BDR FVC (%) | Pre-BDR FEF25–75 (%) | FEV/FVC (%) |
|--------------------------------------------------|---------|-----------------|-----------------------|-------------|
| Proportion with normal lung function             | 28 (26.9) | 44 (42.3)     | 50 (48.1)            | 77 (74.0)   |
| Proportion with abnormal lung function           | 76 (73.1) | 60 (56.7)     | 54 (51.9)            | 72 (66.0)   |

FEV = Forced expiratory volume in 1 s, FVC=Forced vital capacity, FEV/FVC=Ratio of FEV, and FVC, FEF25–75=Forced expiratory flow between 25% and 75% of vital capacity, SAD=Small-airway disease, BDR=Bronchodilator response normalize >=−1.64

Table 5: Mean lung function values analyzed for only children with abnormally low Z-score for forced expiratory volume in 1 s

| Lung function Z-scores pre- and postbronchodilator testing | Mean±SD | P     |
|------------------------------------------------------------|---------|-------|
| FEV             | −2.63±0.79 | 0.003 |
| Pre-BDR         | −2.37±0.99 |       |
| Post-BDR        | −2.24±1.03 | 0.604 |
| Pre-BDR         | −2.19±1.25 |       |
| Post-BDR        | −1.99±1.14 | <0.001|
| FEF25–75        | −1.52±1.27 |       |

FEV=Forced expiratory volume in 1 s, FVC=Forced vital capacity, FEF25–75=Forced expiratory flow between 25% and 75% of vital capacity, BDR=Bronchodilator response, SD=Standard deviation

lower baseline mean Z-scores in HIV-infected children.[14] This finding may be explained by age-related study bias, the possibility of mixed-race population in their study location, and the utilization of the GLI reference equation for African Americans. Our study population was more homogeneously black, which made us resort to the alternative GLI non-Caucasian “other” option.[14] In addition, the most affected lung function parameter was FEV₁, implying that many HIV-infected children are at risk of developing clinical manifestations of obstructive lung disease such as asthma. The FEF25–75 was also substantially abnormal, especially with deranged FEV₁. This observation suggests the possibility of SAD in many of these children. The FVC was notably the least affected. Thus, although some patients had restrictive or fixed airway lung abnormalities, they were not the predominant types within our cohort. Similar studies with larger sample sizes equally showed that obstructive lung disease was a prominent finding.[12,15,22]

The majority of our study participants had a normal FEV₁/FVC ratio which agrees with the pre-BDR findings in another related study,[14] where the cohort was predominantly children with asthma. However, a normal FEV₁/FVC ratio may not always signify a normal lung function but may suggest an obstruction in the presence of normal FVC. We noted that the majority had abnormal FEV₁ with normal FVC, indicating a possible early obstruction. The effect of low and declining FEV₁, if ignored in children with HIV, is further buttressed in the study by Ginthinji et al.[14] in which obstructive spirometry pattern increased from a prevalence of 4.8% at baseline to 8.1% at 24 months. In lung function assessment, FEV₁ as a drawback primarily reflects obstruction in the larger airways, and a significant degree of SAD precedes abnormalities in FEV₁.[6] We also found that among those with abnormalities in FEV₁ (even when positive BDR cutoff was made as high as 20%), more than half of those with abnormal FEV₁ remained positive, further showing that abnormal FEV₁ is to be expected in HIV-infected children. Interestingly, we also noted that when FEV₁ and FEF25–75 were both affected, there was higher certainty for the existence of SAD, coupled with the finding of higher proportion of BDR response for FEV₁. This finding occurred even in patients who initially failed to show abnormal FEF25–75 but showed a significant positive BDR in that regard should be potentially considered as having SAD and their other parameters such as FEV₁ immediately observed or further followed up on a long term. A similar study by Gingo et al.[13] revealed that only 21% of the participants had irreversible airway obstruction based on a postbronchodilator FEV₁/FVC ratio <0.70. Thus, restrictive abnormalities or fixed airway obstructions occur but may not be the significant abnormalities in this group of patients. We also observed that the participants concurrently showed irreversible airway obstruction and an abnormal zFEV₁ once they had low zFVC. Although abnormal zFEV₁ is prevalent in HIV-infected children, the patients’ other parameters suggested restrictive pattern or fixed airway abnormality.

Where the usefulness of FEF25–75 as a marker of SAD remains doubtful, some authors still recognize that with a borderline value of FEV1/FVC, any abnormal FEF25–75 indicates the presence of airway obstruction.[24] Moreover, such FEF25–75 results have helped in the quality control of lung function assessments.[25] Pediatricians should, therefore, pay attention to FEF25–75 values in order to avoid missing SAD. Furthermore, assessment for associated risk factors showed a positive association with zBMI, suggesting that better nourishment (which may increase immunity) may serve as an additional protection from lung infections. The better weight and height, as well as higher zBMI scores, also mean better lung function values. Majority of our patients were reasonably well nourished with good mean zBMI score. Abnormal lung function parameters are thus basically due to the HIV-related effect on the lungs. In tandem with our observation, Arigilani
et al.,[26] using GLI methods, found that malnourished African children with normal FEV\textsubscript{1}/FVC ratio concurrently had significant reductions in FEV\textsubscript{1} and FVC, supporting the positive correlation of nutrition and higher zBMI with lung function outcome.

**Study limitations**

Our sample size was small but was based on the calculated sample size using a previous study conducted in HIV-infected children, making it, nevertheless, appropriate for the study. We gathered information on the CD4+ T-cell count and HAART for each child which may affect lung function outcome interpretation. These were not analyzed further as the enrolled patients were all stable and strictly adhered to HAART. Those who did not meet the inclusion criteria of clinical stability were excluded from participating, to minimize confounders that may affect the interpretation of results. The generalizability of the study findings to HIV-infected children who are not of the same ethnic group may appear as a limitation, but the use of GLI methods puts the ethnic correction into consideration and thus makes the data useful for African children with HIV.

**Conclusion**

Spirometric measurements in HIV-infected African children show that they have SAD. When there is an abnormal lung function parameter (particularly FEV\textsubscript{1}), it is essential to look out for abnormalities in other parameters to help correctly interpret the modality of management. Every child with abnormal FEF\textsubscript{25-75} (a marker of SAD) concurrently has abnormal FE\textsubscript{V}\textsubscript{1}. The reversibility of FEF\textsubscript{25-75} (shown by the positive BDR) was a prominent finding which should be a diagnostic priority. The intervention will help to triage patients that qualify for long-term follow-up of their lung function, especially where resources are scarce to perform routine spirometry on every HIV-infected child.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Verguet S, Norheim OF, Olson ZD, Yamey G, Jamison DT. Annual rates of decline in child, maternal, HIV, and tuberculosis mortality across 109 countries of low and middle income from 1990 to 2013: An assessment of the feasibility of post-2015 goals. Lancet Glob Health 2014;2:e698-709.
2. Joint United Nations Programmes on HIV/AIDS Countdown to Zero. Global Plan Towards the Elimination of New HIV Infections among Children by 2015 and Keeping their Mothers Alive; 2011-2015. Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/20110609_JC2137_Global-Plan-Elimination-HIV-Children_en.pdf. [Last accessed on 2020 Apr 20].
3. Adetokunboh OO, Oluwasanu M. Eliminating mother-to-child transmission of the human immunodeficiency virus in sub-Saharan Africa: The journey so far and what remains to be done. J Infect Public Heal 2016;9:396-407.
4. Drummond MB, Kirk GD. HIV-associated obstructive lung diseases: Insights and implications for the clinician. Lancet Respir Med 2014;2:583-92.
5. Ayuk AC, Ubosie AC, Iloh KK, Obumneme-Anyim IN, Emodi IJ, Ibeziako NS, et al. Pattern of respiratory diseases among human immunodeficiency virus-infected children in Enugu, Nigeria.
Ayuk, et al.: Small-airway disease in children with HIV

Indian J Child Health 2019;6:287-91.

6. McNulty W, Usmani OS. Techniques of assessing small airways dysfunction. Eur Clin Respir J 2014;1:10.3402/ecrj.v1.25898.

7. Rao DR, Griffin JM, Baxi SN, Sheehan WJ, Hoffman EB, Wanda Phipatanakul W. The utility of forced expiratory flow between 25% and 75% of vital capacity in predicting childhood asthma morbidity and severity. J Asthma 2012;49:586-92.

8. Boutin B, Koskas M, Guillo H, Maingot L, La Rocca MC, Boulé M, et al. Forced expiratory flows’ contribution to lung function interpretation in school children. Eur Respir J 2015;45:107-15.

9. Simon MR, Chinchilli VM, Phillips BR, Sorkness CA, Lemanske RF Jr, Szefler SJ, et al. Forced expiratory flow between 25% and 75% of vital capacity and FEV1/forced vital capacity ratio in relation to clinical and physiological parameters in asthmatic children with normal FEV1 values. J Allergy Clin Immunol 2010;126:527-30.

10. Lebecque P, Kiakulanda P, Coates AL. Spirometry in the asthmatic child: Is FEF25-75 a more sensitive test than FEV1/FVC? Pediatr Pulmonol 1993;16:19-22.

11. Ownby DR, Peterson EL, Johnson CC. Factors related to methacholine airway responsiveness in children. Am J Respir Crit Care Med 2000;161:1578-83.

12. Githinji LN, Gray DM, Hlengwa S, Myer L, Zar HJ. Lung function in South African adolescents infected perinatally with HIV and treated long-term with antiretroviral therapy. Ann Am Thorac Soc 2017;14:722-9.

13. Gingo MR, George MP, Kessinger CJ, Lucht L, Rissler B, Weinman R, et al. Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era. Am J Respir Crit Care Med 2010;182:790-6.

14. Githinji LN, Gray DM, Hlengwa S, Machemedze T, Zar HJ. Longitudinal changes in spirometry in South African adolescents perinatally infected with human immunodeficiency virus who are receiving antiretroviral therapy. Clin Infect Dis 2020;70:483-90.

15. Mwalukomo T, Rylance SJ, Webb EL, Anderson S, O’Hare B, van Oosterhout JJ, et al. Clinical characteristics and lung function in older children vertically infected with human immunodeficiency virus in Malawi. J Pediatric Infect Dis Soc 2016;5:161-9.

16. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: The global lung function 2012 equations. Eur Respir J 2012;40:1324-43.

17. Ogunlesi AT, Dedeke IOF, Kuponiyi OT. Socio-economic classification of children attending specialist pediatric centres in Ogun State, Nigeria. Niger Med Pract 2008;54:21-5.

18. Graham BL, Steenbruggen I, Miller MR, Barjakatavecic IZ, Cooper BG, Hall GL, et al. Standardization of spirometry 2019 update. An official American thoracic society and European respiratory society technical statement. Am J Respir Crit Care Med 2019;200:e70-88.

19. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38.

20. American Association of Respiratory Care. Clinical practice guidelines. Spirometry, 1996. Update Respir Care 1996;41:629-36.

21. Boggs PB, Bhat KD, Velovius WA, Debo MS. The clinical significance of volume adjusted maximal mid expiratory flow (isovolume 25–75%) in assessing airway responsiveness to inhaled bronchodilator in asthmatics. Ann Allergy 1982;48:139-42.

22. Drummond MB, Kunisaki KM, Huang L. Obstructive lung diseases in HIV: A clinical review and identification of key future research needs. Semin Respir Crit Care Med 2016;37:277-88.

23. Quanjer PH, Weiner DJ, Prietto JJ, Brazil DJ, Boors PW. Measurement of FEF25–75% and FEI75%does not contribute to clinical decision making. Eur Respir J 2014;43:1051-8.

24. Richter DC, Joubert JR, Nell H, Schuarmans MM, Irusen EM. Diagnostic value of post-bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma. Int J Chron Obstruct Pulmon Dis 2008;3:693-9.

25. Beydon N, Davis SD, Lombardi E, Allen JL, Arets HG, Aurora P, et al. An official American Thoracic Society / European Respiratory Society statement: Pulmonary function testing in preschool children. Am J Respir Crit Care Med 2007;175:1304-45.

26. Arigliani M, Canciani MC, Mottini G, Altomare M, Magnolato A, Loa Clemente SV, et al. Evaluation of the global lung initiative 2012 reference values for spirometry in African children. Am J Respir Crit Care Med 2017;195:229-36.